← Back to Search
Can The Pharmaceutical Industry Reduce Attrition Rates?
I. Kola, John L. Landis
Published 2004 · Business, Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
The pharmaceutical industry faces considerable challenges, both politically and fiscally. Politically, governments around the world are trying to contain costs and, as health care budgets constitute a very significant part of governmental spending, these costs are the subject of intense scrutiny. In the United States, drug costs are also the subject of intense political discourse. This article deals with the fiscal pressures that face the industry from the perspective of R&D. What impinges on productivity? How can we improve current reduced R&D productivity?
This paper references
An animal model for pycnodysostosis: the role of cathepsin K in bone remodelling.
F. Lazner (1999)
Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization
M. Gowen (1999)
Drug discovery—an operating model for a new era
Scott Myers (2001)
BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.
S. Roberds (2001)
Value of novelty?
P. Ma (2002)
B. Booth (2003)
The price of innovation: new estimates of drug development costs.
J. DiMasi (2003)
2003 approvals: a year of innovation and upward trends
S. Frantz (2004)
New technologies that may impact drug discovery in the 5 – 10 year timeframe workshop
This paper is referenced by
Bioreactors and microphysiological systems for adipose-based pharmacologic screening
Mallory D. Griffin (2022)
Absorbing knowledge from an emerging field: The role of interfacing by proponents in big pharma
Angelo K.S. Romasanta (2021)
Prediction of total drug clearance in humans using animal data: proposal of a multimodal learning method based on deep learning.
Hiroaki Iwata (2021)
Pharmaceutical Industry, Academia, Regulatory Authorities and End User Collaboration in Successful Drug Discovery and Development
R. Poduri (2021)
An ensemble learning approach for modeling the systems biology of drug-induced injury
J. Aguirre-Plans (2021)
Challenging the pipeline
P. Loskill (2021)
Virtual Screening of Pharmaceutical Compounds with hERG Inhibitory Activity (Cardiotoxicity) using Ensemble Learning
A. Sarkar (2021)
Development and validation of dual-cardiotoxicity evaluation method based on analysis of field potential and contractile force of human iPSC-derived cardiomyocytes / multielectrode assay platform.
Seul-Gi Lee (2021)
Application of tools and techniques of quality by design in pharmaceutical process
E. V. Gijo (2021)
Creating stem cell‐derived neuromuscular junctions in vitro
Shawn M. Luttrell (2021)
Value of functional in-vivo endpoints in preclinical radiation research.
Berit Kummer (2021)
The Position of ADME Predictions in Multi-Objective QSAR
A. Tsantili-Kakoulidou (2021)
The Transporter-Mediated Cellular Uptake and Efflux of Pharmaceutical Drugs and Biotechnology Products: How and Why Phospholipid Bilayer Transport Is Negligible in Real Biomembranes
Douglas B Kell (2021)
The Application of Mass Spectrometry in Drug Metabolism and Pharmacokinetics.
Ji-Yoon Lee (2021)
The importance of intramolecular hydrogen bonds on the translocation of the small drug piracetam through a lipid bilayer
J. Coimbra (2021)
A spatially resolved mechanistic growth law for cancer drug development predicting tumour growing fractions
Adam Nasim (2021)
Assessment of medical morbidities in a rhesus monkey model of naturally occurring low sociality
A. Myers (2021)
Human in vitro disease models to aid pathway and target discovery for neurological disorders
Bhavana Muralidharan (2021)
Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs
Nalinie Joharatnam-Hogan (2021)
A high-throughput cell-based gaussia luciferase reporter assay for measurement of CYP1A1, CYP2B6, and CYP3A4 induction
Han Li (2021)
Molecular structure simulation of (E)-2-(butan-2-ylidene) hydrazinecarbothioamide using the DFT approach, and antioxidant potential assessment of its complexes
Tahmeena Khan (2021)
ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties
Guoli Xiong (2021)
Nanotheranostics and biocompatibility
I. Sharma (2021)
Alkaloids in Contemporary Drug Discovery to Meet Global Disease Needs
S. Daley (2021)
Quantitative Investigation of Irinotecan Metabolism, Transport, and Gut Microbiome Activation
M. Parvez (2021)
Human Induced Pluripotent Stem Cell-Derived Neural Progenitor Cells Produce Distinct Neural 3D In Vitro Models Depending on Alginate/Gellan Gum/Laminin Hydrogel Blend Properties.
Julia Kapr (2021)
Rushed Innovation: Evidence from Drug Licensing
Manuel Hermosilla (2021)
PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
M. Maneiro (2021)
The Role of Science in Drug Development Decisions
L. Colen (2021)
Translational Block in Stroke: A Constructive and “Out-of-the-Box” Reappraisal
A. Lourbopoulos (2021)
ADMET tools: Prediction and assessment of chemical ADMET properties of NCEs
O. Silakari (2021)
Host bioenergetic parameters reveal cytotoxicity of anti-tuberculosis drugs undetected using conventional viability assays
Bridgette M. Cumming (2021)See more